DE1068357T1 - Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren - Google Patents
Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basierenInfo
- Publication number
- DE1068357T1 DE1068357T1 DE1068357T DE99916365T DE1068357T1 DE 1068357 T1 DE1068357 T1 DE 1068357T1 DE 1068357 T DE1068357 T DE 1068357T DE 99916365 T DE99916365 T DE 99916365T DE 1068357 T1 DE1068357 T1 DE 1068357T1
- Authority
- DE
- Germany
- Prior art keywords
- cxcr
- role
- gene expression
- tumorgenese
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 title abstract 5
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 title abstract 5
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000014509 gene expression Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 101150033839 4 gene Proteins 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000010307 cell transformation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7991698P | 1998-03-30 | 1998-03-30 | |
US10465698P | 1998-10-16 | 1998-10-16 | |
PCT/US1999/007431 WO1999050461A1 (en) | 1998-03-30 | 1999-03-29 | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1068357T1 true DE1068357T1 (de) | 2001-07-19 |
Family
ID=26762563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1068357T Pending DE1068357T1 (de) | 1998-03-30 | 1999-03-29 | Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren |
Country Status (12)
Country | Link |
---|---|
US (3) | US20050202019A1 (de) |
EP (2) | EP2308996A1 (de) |
JP (3) | JP4786793B2 (de) |
AT (1) | ATE525477T1 (de) |
AU (2) | AU766675B2 (de) |
CA (2) | CA2731416A1 (de) |
DE (1) | DE1068357T1 (de) |
DK (1) | DK1068357T3 (de) |
ES (1) | ES2156581T5 (de) |
GR (1) | GR20010300028T1 (de) |
NZ (2) | NZ528767A (de) |
WO (1) | WO1999050461A1 (de) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU766675B2 (en) * | 1998-03-30 | 2003-10-23 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
US6863887B1 (en) | 1998-03-30 | 2005-03-08 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
WO2000031271A1 (fr) * | 1998-11-24 | 2000-06-02 | Hisamitsu Pharmaceutical Co., Inc. | Inhibiteurs d'infections a vih |
US7138496B2 (en) * | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
ATE538785T1 (de) | 2001-07-31 | 2012-01-15 | Genzyme Global S A R L | Verfahren zur mobilisierung von vorläufer/stammzellen |
ATE434040T1 (de) | 2001-10-01 | 2009-07-15 | Dyax Corp | Mehrkettige eukaryontische display-vektoren und deren verwendungen |
US20040009171A1 (en) * | 2001-10-18 | 2004-01-15 | Genentech, Inc. | Methods for the treatment of carcinoma |
US7253007B2 (en) | 2001-11-30 | 2007-08-07 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7928220B2 (en) | 2002-02-20 | 2011-04-19 | Merck Sharp & Dohme Corp. | RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA) |
WO2003080116A1 (en) | 2002-03-21 | 2003-10-02 | University Of Florida | Modulating angiogenesis |
US20090291087A1 (en) * | 2002-03-21 | 2009-11-26 | University Of Florida Research Foundation, Inc. | Modulating angiogenesis |
US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
US8512701B2 (en) | 2002-11-15 | 2013-08-20 | Morehouse School Of Medicine | Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
US8658377B2 (en) | 2002-11-15 | 2014-02-25 | Morehouse School Of Medicine | Detecting cancer with anti-CCL25 and anti-CCR9 antibodies |
US7919083B2 (en) | 2002-11-15 | 2011-04-05 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
US9233120B2 (en) | 2002-11-15 | 2016-01-12 | Jyant Technologies | Anti-CCL25 and anti-CCR9 antibodies for the prevention and treatment of cancer and cancer cell migration |
WO2004055041A2 (en) * | 2002-12-13 | 2004-07-01 | Case Western Reserve University | Defensin-inducing peptides from fusobacterium |
CN1747929B (zh) | 2002-12-20 | 2010-04-28 | 坎莫森特里克斯公司 | 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂 |
DK1871804T3 (da) | 2005-04-21 | 2013-12-02 | Chemocentryx Inc | Antistoffer, der binder CCX-CKR2 |
WO2006126209A1 (en) * | 2005-05-26 | 2006-11-30 | Rappaport Family Institute For Research In The Medical Sciences | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions |
US20070123448A1 (en) * | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
CA2638807A1 (en) * | 2006-02-01 | 2007-08-09 | The Burnham Institute For Medical Research | Lymphatic zip codes in tumors and pre-malignant lesions |
EP2046834B9 (de) * | 2006-08-11 | 2013-04-10 | Ono Pharmaceutical Co., Ltd. | Monoklonale antikörper gegen stromal derived factor-1 (sdf-1-) |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
EP2142206B1 (de) | 2007-03-30 | 2014-07-30 | The Cleveland Clinic Foundation | SDf-1 zur Verwendung bei der Behandlung der ischämischen peripheren Gefäßerkrankungen |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
EP3124497B1 (de) | 2007-09-14 | 2020-04-15 | Adimab, LLC | Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon |
EP2237798A2 (de) | 2007-12-12 | 2010-10-13 | Imperial Innovations Limited | Verfahren |
US20100272679A1 (en) | 2007-12-14 | 2010-10-28 | Penn Marc S | Compositions and methods of promoting wound healing |
GB0802754D0 (en) * | 2008-02-14 | 2008-03-26 | Inst Superiore Di Sanito | Antisense RNA targetting CXCR4 |
US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
RU2010151725A (ru) | 2008-05-16 | 2012-06-27 | Аблинкс Нв (Be) | Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их |
CN103396473A (zh) | 2008-11-04 | 2013-11-20 | 安科治疗公司 | Cxcr4受体化合物 |
CA2772610C (en) | 2009-08-28 | 2018-01-23 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
US9155795B2 (en) | 2010-02-26 | 2015-10-13 | Anchor Therapeutics, Inc. | CXCR4 receptor compounds |
WO2011117423A1 (en) | 2010-03-26 | 2011-09-29 | Ablynx N.V. | Immunoglobulin single variable domains directed against cxcr7 |
AU2011279073B2 (en) | 2010-07-16 | 2016-06-09 | Adimab, Llc | Antibody libraries |
AU2011300818B2 (en) * | 2010-09-09 | 2015-11-12 | TME Pharma AG | SDF-1 binding nucleic acids and the use thereof in cancer treatment |
AU2012234284B2 (en) | 2011-03-28 | 2015-10-08 | Ablynx Nv | Bispecific anti-CXCR7 immunoglobulin single variable domains |
BR112013029482A2 (pt) | 2011-05-16 | 2016-08-09 | Genzyme Corp | utilização de antagonistas cxr4 |
ES2758884T3 (es) | 2011-06-24 | 2020-05-06 | Stephen D Gillies | Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas |
AR087364A1 (es) | 2011-07-29 | 2014-03-19 | Pf Medicament | Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres |
AR087363A1 (es) | 2011-07-29 | 2014-03-19 | Pf Medicament | Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres |
CN105518146B (zh) * | 2013-04-04 | 2022-07-15 | 哈佛学院校长同事会 | 利用CRISPR/Cas***的基因组编辑的治疗性用途 |
EP3019595A4 (de) | 2013-07-09 | 2016-11-30 | Therapeutische verwendungen einer genomänderung mit crispr-/cas-systemen | |
HUP1300509A2 (hu) * | 2013-08-30 | 2015-03-30 | Gabor Firneisz | CXCL12 (Chemokine (C-X-C motif) Ligand 12) és IGFBP2 (Insulin-Like Growth Factor Binding Protein 2) gátlók cukorbetegséggel összefüggõ hasnyálmirigyrák kezelésénél történõ alkalmazásra |
EP3389720A1 (de) | 2015-12-18 | 2018-10-24 | The General Hospital Corporation | Polyacetalpolymere, konjugate, partikel und verwendungen davon |
EP3471754A1 (de) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1-antikörper |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
AU2018253115B2 (en) | 2017-04-12 | 2022-08-11 | Edigene Biotechnology, Inc. | Aryl hydrocarbon receptor antagonists and uses thereof |
EP3703715A1 (de) | 2017-10-31 | 2020-09-09 | Magenta Therapeutics, Inc. | Zusammensetzungen und verfahren für hämatopoietische stamm- und vorläuferzelltransplantationstherapie |
CA3079405A1 (en) | 2017-10-31 | 2019-05-09 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
BR112020011186A2 (pt) | 2017-12-06 | 2020-11-17 | Magenta Therapeutics, Inc. | regimes de dosagem para a mobilização de células-tronco e progenitoras hematopoiéticas |
US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
WO2019136159A1 (en) | 2018-01-03 | 2019-07-11 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
EP4051298A1 (de) | 2019-11-01 | 2022-09-07 | Magenta Therapeutics, Inc. | Dosierschema zur mobilisierung von hämatopoetischen stammzellen und vorläuferzellen |
EP4143302A1 (de) | 2020-04-27 | 2023-03-08 | Magenta Therapeutics, Inc. | Verfahren und zusammensetzungen zur transduktion hämatopoetischer stamm- und vorläuferzellen in vivo |
WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
CA1289880C (en) * | 1985-12-06 | 1991-10-01 | Jeffrey L. Winkelhake | Anti-human ovarian cancer immunotoxins and methods of use thereof |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
AU622426B2 (en) | 1987-12-11 | 1992-04-09 | Abbott Laboratories | Assay using template-dependent nucleic acid probe reorganization |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
CA2006408A1 (en) * | 1988-12-27 | 1990-06-27 | Susumu Iwasa | Bispecific monoclonal antibody, its production and use |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
JP3127158B2 (ja) | 1989-10-05 | 2001-01-22 | オプテイン,インコーポレイティド | 新規の遺伝子及びポリペチドの無細胞合成並びに単離 |
US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
CA2092323A1 (en) | 1990-10-01 | 1992-04-02 | George Y. Wu | Targeting viruses and cells for selective internalization by cells |
US5776457A (en) * | 1991-03-29 | 1998-07-07 | Genentech, Inc. | Antibodies to human PF4A receptor and compositions thereof |
US5543503A (en) * | 1991-03-29 | 1996-08-06 | Genentech Inc. | Antibodies to human IL-8 type A receptor |
US5840856A (en) * | 1991-03-29 | 1998-11-24 | Genentech, Inc. | Antibodies to a human PF4 superfamily receptor |
DE69231223T3 (de) | 1991-03-29 | 2008-01-17 | Genentech, Inc., South San Francisco | Menschliche pf4a rezeptoren und ihre verwendung |
DK0584279T3 (da) | 1991-05-14 | 2001-06-11 | Immune Response Corp Inc | Målrettet aflevering af gener, som koder for immunogene proteiner |
ES2149774T3 (es) | 1991-06-05 | 2000-11-16 | Univ Connecticut | Aportacion dirigida de genes que codifican proteinas secretoras. |
WO1993014188A1 (en) | 1992-01-17 | 1993-07-22 | The Regents Of The University Of Michigan | Targeted virus |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
AU3940293A (en) | 1992-04-03 | 1993-11-08 | Alexander T. YOUNG | Gene therapy using targeted viral vectors |
AU689758B2 (en) | 1992-10-09 | 1998-04-09 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
JP3367581B2 (ja) * | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするdna、そのdnaからなるベクター、そのベクターで形質転換された宿主細胞 |
WO1997028258A1 (en) * | 1996-01-30 | 1997-08-07 | The National Institutes Of Health | Cells expressing both human cd4 and cxcr4 |
AU3505397A (en) * | 1996-06-25 | 1998-01-14 | Trustees Of The University Of Pennsylvania, The | Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same |
FR2751658B1 (fr) * | 1996-07-26 | 1998-10-02 | Pasteur Institut | Utilisation d'une chemokine (sdf-1) ligand pour le recepteur de lestr/fusin/cxcr4 pour prevenir ou traiter l'infection par des virus de type vih |
US5939538A (en) * | 1996-10-25 | 1999-08-17 | Immusol Incorporated | Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA |
WO2000009152A1 (en) | 1998-08-14 | 2000-02-24 | The University Of British Columbia | Therapeutic chemokine receptor antagonists |
DE69914463T2 (de) * | 1998-03-13 | 2004-11-11 | The University Of British Columbia, Vancouver | Therapeutische chemokine rezeptor antagonisten |
EP1745797A3 (de) | 1998-03-24 | 2007-07-18 | Chugai Seiyaku Kabushiki Kaisha | Inhibitoren der Vaskularisierung |
AU766675B2 (en) | 1998-03-30 | 2003-10-23 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis |
WO1999065507A1 (en) * | 1998-06-19 | 1999-12-23 | The General Hospital Corporation | Modulating platelet function |
US6949243B1 (en) * | 1999-11-24 | 2005-09-27 | Schering Corporation | Methods of inhibiting metastasis |
US9002545B2 (en) | 2011-01-07 | 2015-04-07 | Wabtec Holding Corp. | Data improvement system and method |
-
1999
- 1999-03-29 AU AU34702/99A patent/AU766675B2/en not_active Ceased
- 1999-03-29 WO PCT/US1999/007431 patent/WO1999050461A1/en active IP Right Grant
- 1999-03-29 NZ NZ528767A patent/NZ528767A/en unknown
- 1999-03-29 EP EP10184637A patent/EP2308996A1/de not_active Withdrawn
- 1999-03-29 DE DE1068357T patent/DE1068357T1/de active Pending
- 1999-03-29 EP EP99916365.2A patent/EP1068357B2/de not_active Expired - Lifetime
- 1999-03-29 CA CA2731416A patent/CA2731416A1/en not_active Abandoned
- 1999-03-29 DK DK99916365.2T patent/DK1068357T3/da active
- 1999-03-29 AT AT99916365T patent/ATE525477T1/de active
- 1999-03-29 ES ES99916365.2T patent/ES2156581T5/es not_active Expired - Lifetime
- 1999-03-29 CA CA2323525A patent/CA2323525C/en not_active Expired - Fee Related
- 1999-03-29 NZ NZ507161A patent/NZ507161A/en unknown
- 1999-03-29 JP JP2000541348A patent/JP4786793B2/ja not_active Expired - Fee Related
-
2001
- 2001-06-29 GR GR20010300028T patent/GR20010300028T1/el unknown
-
2004
- 2004-02-12 AU AU2004200560A patent/AU2004200560B2/en not_active Ceased
- 2004-11-09 US US10/985,324 patent/US20050202019A1/en not_active Abandoned
-
2009
- 2009-02-06 US US12/367,308 patent/US8409566B2/en not_active Expired - Fee Related
-
2010
- 2010-10-01 JP JP2010224077A patent/JP2011021030A/ja not_active Withdrawn
-
2013
- 2013-04-02 US US13/855,626 patent/US9566294B2/en not_active Expired - Fee Related
- 2013-11-25 JP JP2013243021A patent/JP5992897B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1999050461A9 (en) | 2000-02-17 |
AU2004200560A1 (en) | 2004-03-11 |
JP2014043460A (ja) | 2014-03-13 |
US20050202019A1 (en) | 2005-09-15 |
CA2323525A1 (en) | 1999-10-07 |
US8409566B2 (en) | 2013-04-02 |
ES2156581T5 (es) | 2015-01-21 |
ATE525477T1 (de) | 2011-10-15 |
US20100062003A1 (en) | 2010-03-11 |
EP1068357A1 (de) | 2001-01-17 |
JP2002509734A (ja) | 2002-04-02 |
JP5992897B2 (ja) | 2016-09-14 |
WO1999050461A1 (en) | 1999-10-07 |
DK1068357T3 (da) | 2011-12-12 |
JP2011021030A (ja) | 2011-02-03 |
AU766675B2 (en) | 2003-10-23 |
NZ507161A (en) | 2003-12-19 |
EP1068357B2 (de) | 2014-12-10 |
CA2323525C (en) | 2011-03-01 |
AU3470299A (en) | 1999-10-18 |
US20140072564A1 (en) | 2014-03-13 |
EP1068357B1 (de) | 2011-09-21 |
GR20010300028T1 (en) | 2001-06-29 |
JP4786793B2 (ja) | 2011-10-05 |
ES2156581T3 (es) | 2012-02-03 |
EP2308996A1 (de) | 2011-04-13 |
CA2731416A1 (en) | 1999-10-07 |
EP1068357A4 (de) | 2003-07-16 |
AU2004200560B2 (en) | 2007-09-20 |
NZ528767A (en) | 2005-08-26 |
US9566294B2 (en) | 2017-02-14 |
ES2156581T1 (es) | 2001-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1068357T1 (de) | Therapeutische und diagnostische anwendungen welche auf der rolle von cxcr-4 in der tumorgenese basieren | |
BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
DE59903921D1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
MX230771B (es) | Aril o heteroarilamidas sustituidas que tienen actividad biologica similar a los retinoides. | |
HK1032050A1 (en) | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas. | |
IL100810A0 (en) | Tetrahydropyrimidine derivatives and pharmaceutical compositions comprising them | |
TW263423B (de) | ||
DE60218458D1 (de) | Isochinolinon derivate als parp inhibitoren | |
MXPA02008056A (es) | Derivados de 2-oxo-1 pirrolidina, proceso para prepararlos y sus aplicaciones. | |
ATE412052T1 (de) | Synthetische polynukleotide | |
ES2194960T3 (es) | N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f. | |
ATE227277T1 (de) | Isoxazoline derivate und ihre verwendung als antimikroben | |
ATE342911T1 (de) | Synthese von nukleosiden und polynukleotiden | |
DE69824433D1 (en) | Proteintyrosinphosphatase inhibitoren | |
TR199801871A2 (xx) | Bifenilsulfonilsiyanamidler �retim y�ntemi ve ila� olarak kullan�mlar�. | |
DE69937301D1 (de) | Aminosterolderivate und ihre verwendungen | |
ZA961364B (en) | 1-Aryl-2-acylamino-ethane compounds | |
IL131407A0 (en) | Tetrahydropyrido compounds medicaments containing the same and the use thereof | |
MX9604762A (es) | Nuevas sulfonamidas y procedimiento para su preparacion. | |
HUP0100611A2 (hu) | Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére | |
ES2110258T3 (es) | Derivados de 1,3,5(10)-estratrieno activos por via oral. | |
NO20003397D0 (no) | 3 '-empiriske K-252A-derivater | |
DE69724548D1 (de) | Substituierte 2,3-Aryl-Benzothiophene und ihre östrogene Aktivität | |
ITRM920305A0 (it) | Composizione farmaceutica per il trattamento dello shock, particolarmente dello shock cardiogeno e dello shock settico. |